Clinical Trials

24 enrolled

Phase 1/2 Active not recruiting

Colonic Neoplasms, Colorectal Neoplasms

NCT05846867 2026-03-04

A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer

170 enrolled

Colorectal Neoplasms

NCT05838768 2026-02-06

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

327 enrolled

Turcot syndrome, Neoplasm Metastasis, Colorectal Neoplasms

NCT04587128 2026-02-05

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

34 enrolled

Colorectal Neoplasms

NCT05843188 2025-12-09

Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer

155 enrolled

Phase 3 Active not recruiting

Colorectal Neoplasms

NCT03829462 2025-11-21

NEXT-REGIRI

377 enrolled 30 charts

Colorectal Neoplasms

NCT02595931 2025-11-17

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

66 enrolled

GastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT05382442 2025-10-14

A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer

254 enrolled

Phase 3 Active not recruiting

Colorectal Neoplasms

NCT04008030 2025-10-03

CheckMate 8HW

839 enrolled 22 charts 1 FDA

Colorectal Neoplasms

NCT01787500 2025-09-09

Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

33 enrolled

Noonan syndrome 3, Neoplasm Metastasis, Colorectal Neoplasms

NCT00492999 2025-08-17

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

64 enrolled

Phase 3 Active not recruiting

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT04607421 2025-08-14

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

831 enrolled 2 FDA

Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms

NCT03493048 2025-08-03

Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM

146 enrolled

Colorectal Neoplasms

NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

DermatologicGastrointestinalGenitourinaryGynecologic

138 enrolled

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03368963 2025-01-07

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

Phase 1/2 Active not recruiting

64 enrolled

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT01531595 2024-12-12

AXOAXI

100 enrolled

Colorectal Neoplasms

NCT03678883 2024-11-07

9-ING-41 in Patients with Advanced Cancers

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

350 enrolled

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT04535401 2024-10-10

Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

10 enrolled

Stomach Neoplasms, Colorectal Neoplasms

NCT04117945 2024-09-27

Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

22 enrolled 17 charts

Colorectal Neoplasms

NCT06403709 2024-09-24

Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients

35 enrolled